Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Drug Chem Toxicol ; 46(2): 323-329, 2023 Mar.
Article in English | MEDLINE | ID: mdl-35057671

ABSTRACT

Methotrexate (MTX) has been in use for the treatment of rheumatoid arthritis (RA), psoriasis, and cancer since 1948. Its toxic side effects on tissues and organs have been well documented but splenotoxicity has not been addressed. This study set out to investigate this issue by examining the effectiveness of anti-TNFα agents against MTX-induced toxicity in T lymphocytes and macrophages via the regulation of CD3, CD68, and CD200R. Twenty-four Sprague Dawley rats were allocated to three groups: control (received saline solution only), MTX (20 mg/kg of single-dose of MTX), and Ada + MTX (single dose of 10 mg/kg Adalimumab before MTX administration). The spleens were removed 5 days after MTX administration. The number of CD3+/mm3cells for the control, MTX and Ada + MTX groups were, respectively, 2.69 ± 0.86, 20.51 ± 2.7, (p = 0.000) and 11.07 ± 2.01 (p = 0.000). The number of CD68+ macrophages/mm3 in the control, MTX and Ada + MTX groups were, respectively, 8.62 ± 1.08, 38.19 ± 1.37 (p = 0.000), and 16.87 ± 12.57 (p = 0.000). The number of macrophages that were CD200R+/mm3 in the control, MTX, and Ada + MTX groups were 3.33 ± 1.66, 25.77 ± 2.37 (p = 0.000), and 8.68 ± 2.66 (p = 0.000), respectively. We also observed that Ada reduced the numerical densities of these cells following MTX administration (p < 0.05). Ada may, therefore, be a promising candidate for the prevention of the deleterious effects on T lymphocytes and macrophages of MTX-induced toxicity.


Subject(s)
Methotrexate , Spleen , Rats , Animals , Rats, Sprague-Dawley , Adalimumab/toxicity , Methotrexate/toxicity , Macrophages
2.
J Coll Physicians Surg Pak ; 32(10): 1260-1265, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36205268

ABSTRACT

OBJECTIVE: To determine the effect of point-of-care ultrasound (POCUS) performed during the initial evaluation phase of patients with acute abdominal pain. STUDY DESIGN: Randomised controlled, parallel-group trial. PLACE AND DURATION OF STUDY: Sakarya University Training and Research Hospital, Sakarya, Turkey, from October 2019 to March 2020. METHODOLOGY: Patients who presented to the Emergency Department (ED) with acute abdominal pain were included in the study. Exclusion criteria were permanent mental disability, age <18 years, abdominal trauma within the last 24 hours, pregnancy, morbid obesity, repeated admissions, referral from an external centre to the ED, and missing patient information. Patients were divided randomly into two groups: The control group where standard diagnostic strategies were applied and the POCUS group where POCUS was performed together with standard diagnostic strategies. The length of stay (LOS), differential diagnoses, cost and hospitalisation or discharge from ED were compared. RESULTS: The application of POCUS reduced the average number of preliminary differential diagnoses from four to two (p <0.001). Regarding patient outcomes, POCUS reduced LOS in ED in both the discharged and hospitalised patients (p = 0.003, and p = 0.049, respectively). In all patients, POCUS reduced LOS in ED but led to no significant changes in cost (p <0.001, p = and 0.403, respectively). CONCLUSION: POCUS in patients with acute abdominal pain is very useful in reducing the number of differential diagnoses and LOS in ED. KEY WORDS: Abdominal pain, Cost, Emergency department, Length of stay, Point-of-care ultrasound.


Subject(s)
Pain Management , Point-of-Care Systems , Abdominal Pain/diagnostic imaging , Abdominal Pain/etiology , Adolescent , Emergency Service, Hospital , Female , Humans , Pregnancy , Prospective Studies , Ultrasonography
3.
Front Immunol ; 13: 1011935, 2022.
Article in English | MEDLINE | ID: mdl-36923729

ABSTRACT

Older people have difficulty controlling infection with common viruses such as influenza A virus (IAV), RNA virus which causes recurrent infections due to a high rate of genetic mutation, and Epstein Barr virus (EBV), DNA virus which persists in B cells for life in the 95% of people that become acutely infected. We questioned whether changes in epitope-specific memory CD8 T cell receptor (TCR) repertoires to these two common viruses could occur with increasing age and contribute to waning immunity. We compared CD8 memory TCR alpha and beta repertoires in two HLA-A2+ EBV- and IAV-immune donors, young (Y) and older (O) donors to three immunodominant epitopes known to be cross-reactive, IAV-M158-66 (IAV-M1), EBV-BMLF1280-288 (EBV-BM), and EBV-BRLF1109-117 (EBV-BR). We, therefore, also designed these studies to examine if TCR cross-reactivity could contribute to changes in repertoire with increasing age. TCR high throughput sequencing showed a significant difference in the pattern of TRBV usage between Y and O. However, there were many more differences in AV and AJ usage, between the age groups suggesting that changes in TCRα usage may play a greater role in evolution of the TCR repertoire emphasizing the importance of studying TRAV repertoires. With increasing age there was a preferential retention of TCR for all three epitopes with features in their complementarity-determining region (CDR3) that increased their ease of generation, and their cross-reactive potential. Young and older donors differed in the patterns of AV/AJ and BV/BJ pairings and usage of dominant CDR3 motifs specific to all three epitopes. Both young and older donors had cross-reactive responses between these 3 epitopes, which were unique and differed from the cognate responses having features that suggested they could interact with either ligand. There was an increased tendency for the classic IAV-M1 specific clone BV19-IRSS-JB2.7/AV27-CAGGGSQGNLIF-AJ42 to appear among the cross-reactive clones, suggesting that the dominance of this clone may relate to its cross-reactivity with EBV. These results suggest that although young and older donors retain classic TCR features for each epitope their repertoires are gradually changing with age, maintaining TCRs that are cross-reactive between these two common human viruses, one with recurrent infections and the other a persistent virus which frequently reactivates.


Subject(s)
Epstein-Barr Virus Infections , Influenza A virus , Humans , Aged , Herpesvirus 4, Human , Epstein-Barr Virus Infections/genetics , Reinfection , CD8-Positive T-Lymphocytes , Receptors, Antigen, T-Cell, alpha-beta/genetics , Receptors, Antigen, T-Cell/genetics , Complementarity Determining Regions , Epitopes
4.
mBio ; 11(2)2020 03 17.
Article in English | MEDLINE | ID: mdl-32184241

ABSTRACT

Recognition modes of individual T cell receptors (TCRs) are well studied, but factors driving the selection of TCR repertoires from primary through persistent human virus infections are less well understood. Using deep sequencing, we demonstrate a high degree of diversity of Epstein-Barr virus (EBV)-specific clonotypes in acute infectious mononucleosis (AIM). Only 9% of unique clonotypes detected in AIM persisted into convalescence; the majority (91%) of unique clonotypes detected in AIM were not detected in convalescence and were seeming replaced by equally diverse "de novo" clonotypes. The persistent clonotypes had a greater probability of being generated than nonpersistent clonotypes due to convergence recombination of multiple nucleotide sequences to encode the same amino acid sequence, as well as the use of shorter complementarity-determining regions 3 (CDR3s) with fewer nucleotide additions (i.e., sequences closer to germ line). Moreover, the two most immunodominant HLA-A2-restricted EBV epitopes, BRLF1109 and BMLF1280, show highly distinct antigen-specific public (i.e., shared between individuals) features. In fact, TCRα CDR3 motifs played a dominant role, while TCRß played a minimal role, in the selection of TCR repertoire to an immunodominant EBV epitope, BRLF1. This contrasts with the majority of previously reported repertoires, which appear to be selected either on TCRß CDR3 interactions with peptide/major histocompatibility complex (MHC) or in combination with TCRα CDR3. Understanding of how TCR-peptide-MHC complex interactions drive repertoire selection can be used to develop optimal strategies for vaccine design or generation of appropriate adoptive immunotherapies for viral infections in transplant settings or for cancer.IMPORTANCE Several lines of evidence suggest that TCRα and TCRß repertoires play a role in disease outcomes and treatment strategies during viral infections in transplant patients and in cancer and autoimmune disease therapy. Our data suggest that it is essential that we understand the basic principles of how to drive optimum repertoires for both TCR chains, α and ß. We address this important issue by characterizing the CD8 TCR repertoire to a common persistent human viral infection (EBV), which is controlled by appropriate CD8 T cell responses. The ultimate goal would be to determine if the individuals who are infected asymptomatically develop a different TCR repertoire than those that develop the immunopathology of AIM. Here, we begin by doing an in-depth characterization of both CD8 T cell TCRα and TCRß repertoires to two immunodominant EBV epitopes over the course of AIM, identifying potential factors that may be driving their selection.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Herpesvirus 4, Human/genetics , Immunodominant Epitopes/genetics , Major Histocompatibility Complex , Receptors, Antigen, T-Cell, alpha-beta/genetics , Recombination, Genetic , Adolescent , Female , Herpesvirus 4, Human/immunology , Humans , Immunodominant Epitopes/immunology , Male , Receptors, Antigen, T-Cell, alpha-beta/immunology
5.
PLoS Pathog ; 15(11): e1008122, 2019 11.
Article in English | MEDLINE | ID: mdl-31765434

ABSTRACT

The T cell receptor (TCR) repertoire is an essential component of the CD8 T-cell immune response. Here, we seek to investigate factors that drive selection of TCR repertoires specific to the HLA-A2-restricted immunodominant epitope BRLF1109-117 (YVLDHLIVV) over the course of primary Epstein Barr virus (EBV) infection. Using single-cell paired TCRαß sequencing of tetramer sorted CD8 T cells ex vivo, we show at the clonal level that recognition of the HLA-A2-restricted BRLF1 (YVL-BR, BRLF-1109) epitope is mainly driven by the TCRα chain. For the first time, we identify a CDR3α (complementarity determining region 3 α) motif, KDTDKL, resulting from an obligate AV8.1-AJ34 pairing that was shared by all four individuals studied. This observation coupled with the fact that this public AV8.1-KDTDKL-AJ34 TCR pairs with multiple different TCRß chains within the same donor (median 4; range: 1-9), suggests that there are some unique structural features of the interaction between the YVL-BR/MHC and the AV8.1-KDTDKL-AJ34 TCR that leads to this high level of selection. Newly developed TCR motif algorithms identified a lysine at position 1 of the CDR3α motif that is highly conserved and likely important for antigen recognition. Crystal structure analysis of the YVL-BR/HLA-A2 complex revealed that the MHC-bound peptide bulges at position 4, exposing a negatively charged aspartic acid that may interact with the positively charged lysine of CDR3α. TCR cloning and site-directed mutagenesis of the CDR3α lysine ablated YVL-BR-tetramer staining and substantially reduced CD69 upregulation on TCR mutant-transduced cells following antigen-specific stimulation. Reduced activation of T cells expressing this CDR3 motif was also observed following exposure to mutated (D4A) peptide. In summary, we show that a highly public TCR repertoire to an immunodominant epitope of a common human virus is almost completely selected on the basis of CDR3α and provide a likely structural basis for the selection. These studies emphasize the importance of examining TCRα, as well as TCRß, in understanding the CD8 T cell receptor repertoire.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Complementarity Determining Regions/immunology , Epstein-Barr Virus Infections/immunology , Herpesvirus 4, Human/immunology , Immediate-Early Proteins/immunology , Immunodominant Epitopes/immunology , Receptors, Antigen, T-Cell, alpha-beta/immunology , T-Lymphocytes, Cytotoxic/immunology , Trans-Activators/immunology , Amino Acid Sequence , Complementarity Determining Regions/genetics , Complementarity Determining Regions/metabolism , Epitopes, T-Lymphocyte/immunology , Epstein-Barr Virus Infections/virology , HLA-A2 Antigen/immunology , Humans , Immediate-Early Proteins/genetics , Immediate-Early Proteins/metabolism , Peptide Fragments/immunology , Receptors, Antigen, T-Cell, alpha-beta/genetics , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Trans-Activators/genetics , Trans-Activators/metabolism
6.
mBio ; 8(6)2017 Dec 05.
Article in English | MEDLINE | ID: mdl-29208744

ABSTRACT

Fifty years after the discovery of Epstein-Barr virus (EBV), it remains unclear how primary infection with this virus leads to massive CD8 T-cell expansion and acute infectious mononucleosis (AIM) in young adults. AIM can vary greatly in severity, from a mild transient influenza-like illness to a prolonged severe syndrome. We questioned whether expansion of a unique HLA-A2.01-restricted, cross-reactive CD8 T-cell response between influenza virus A-M158 (IAV-M1) and EBV BMLF1280 (EBV-BM) could modulate the immune response to EBV and play a role in determining the severity of AIM in 32 college students. Only ex vivo total IAV-M1 and IAV-M1+EBV-BM cross-reactive tetramer+ frequencies directly correlated with AIM severity and were predictive of severe disease. Expansion of specific cross-reactive memory IAV-M1 T-cell receptor (TCR) Vß repertoires correlated with levels of disease severity. There were unique profiles of qualitatively different functional responses in the cross-reactive and EBV-specific CD8 T-cell responses in each of the three groups studied, severe-AIM patients, mild-AIM patients, and seropositive persistently EBV-infected healthy donors, that may result from differences in TCR repertoire use. IAV-M1 tetramer+ cells were functionally cross-reactive in short-term cultures, were associated with the highest disease severity in AIM, and displayed enhanced production of gamma interferon, a cytokine that greatly amplifies immune responses, thus frequently contributing to induction of immunopathology. Altogether, these data link heterologous immunity via CD8 T-cell cross-reactivity to CD8 T-cell repertoire selection, function, and resultant disease severity in a common and important human infection. In particular, it highlights for the first time a direct link between the TCR repertoire with pathogenesis and the diversity of outcomes upon pathogen encounter.IMPORTANCE The pathogenic impact of immune responses that by chance cross-react to unrelated viruses has not been established in human infections. Here, we demonstrate that the severity of acute infectious mononucleosis (AIM), an Epstein-Barr virus (EBV)-induced disease prevalent in young adults but not children, is associated with increased frequencies of T cells cross-reactive to EBV and the commonly acquired influenza A virus (IAV). The T-cell receptor (TCR) repertoire and functions of these cross-reactive T cells differed between mild- and severe-AIM patients, most likely because these two groups of patients had selected different memory TCR repertoires in response to IAV infections encountered earlier. This heterologous immunity may explain variability in disease outcome and why young adults with more-developed IAV-specific memory T-cell pools have more-severe disease than children, who have less-developed memory pools. This study provides a new framework for understanding the role of heterologous immunity in human health and disease and highlights an important developing field examining the role of T-cell repertoires in the mediation of immunopathology.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Immunologic Memory , Infectious Mononucleosis/immunology , Influenza, Human/immunology , Receptors, Antigen, T-Cell/immunology , Viral Matrix Proteins/immunology , Antigens, Viral/immunology , Cross Reactions/immunology , Epitopes, T-Lymphocyte/immunology , Epitopes, T-Lymphocyte/metabolism , Female , HLA-A2 Antigen/immunology , Herpesvirus 4, Human/immunology , Humans , Immunity, Heterologous , Influenza A virus/immunology , Interferon-gamma/metabolism , Lymphocyte Activation , Male , Receptors, Antigen, T-Cell/metabolism , Severity of Illness Index , Young Adult
8.
Trans R Soc Trop Med Hyg ; 109(1): 62-9, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25573110

ABSTRACT

This review discusses three inter-related topics: (1) the immaturity of the neonatal and infant immune response; (2) heterologous immunity, where prior infection history with unrelated pathogens alters disease outcome resulting in either enhanced protective immunity or increased immunopathology to new infections, and (3) epidemiological human vaccine studies that demonstrate vaccines can have beneficial or detrimental effects on subsequent unrelated infections. The results from the epidemiological and heterologous immunity studies suggest that the immune system has tremendous plasticity and that each new infection or vaccine that an individual is exposed to during a lifetime will potentially alter the dynamics of their immune system. It also suggests that each new infection or vaccine that an infant receives is not only perturbing the immune system but is educating the immune system and laying down the foundation for all subsequent responses. This leads to the question, is there an optimum way to educate the immune system? Should this be taken into consideration in our vaccination protocols?


Subject(s)
Immunity, Heterologous/drug effects , Immunity, Innate/drug effects , Immunologic Memory/drug effects , Vaccination , Viral Vaccines/immunology , Virus Diseases/prevention & control , Animals , Cross Reactions , Humans , Immunity, Heterologous/immunology , Immunity, Innate/immunology , Infant , Infant, Newborn , T-Lymphocytes , Virus Diseases/immunology
10.
J Immunol ; 185(11): 6753-64, 2010 Dec 01.
Article in English | MEDLINE | ID: mdl-21048112

ABSTRACT

Memory T cells cross-reactive with epitopes encoded by related or even unrelated viruses may alter the immune response and pathogenesis of infection by a process known as heterologous immunity. Because a challenge virus epitope may react with only a subset of the T cell repertoire in a cross-reactive epitope-specific memory pool, the vigorous cross-reactive response may be narrowly focused, or oligoclonal. We show in this article, by examining human T cell cross-reactivity between the HLA-A2-restricted influenza A virus-encoded M1(58-66) epitope (GILGFVFTL) and the dissimilar Epstein-Barr virus-encoded BMLF1(280-288) epitope (GLCTLVAML), that, under some conditions, heterologous immunity can lead to a significant broadening, rather than a narrowing, of the TCR repertoire. We suggest that dissimilar cross-reactive epitopes might generate a broad, rather than a narrow, T cell repertoire if there is a lack of dominant high-affinity clones; this hypothesis is supported by computer simulation.


Subject(s)
Epitopes, T-Lymphocyte/metabolism , Herpesvirus 4, Human/immunology , Herpesvirus 4, Human/metabolism , Influenza A virus/immunology , Influenza A virus/metabolism , Receptors, Antigen, T-Cell/metabolism , Adolescent , Adult , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/virology , Clone Cells , Cross Reactions , HLA-A2 Antigen/immunology , HLA-A2 Antigen/metabolism , Humans , Immunodominant Epitopes/metabolism , Middle Aged , Oligopeptides/immunology , Oligopeptides/metabolism , Peptide Fragments/immunology , Peptide Fragments/metabolism , Viral Matrix Proteins/immunology , Viral Matrix Proteins/metabolism , Young Adult
11.
J Immunol ; 184(6): 2825-38, 2010 Mar 15.
Article in English | MEDLINE | ID: mdl-20164414

ABSTRACT

In this study, we demonstrate complex networks of CD8 T cell cross-reactivities between influenza A virus and EBV in humans and between lymphocytic choriomeningitis virus and vaccinia virus in mice. We also show directly that cross-reactive T cells mediate protective heterologous immunity in mice. Subsets of T cell populations reactive with one epitope cross-reacted with either of several other epitopes encoded by the same or the heterologous virus. Human T cells specific to EBV-encoded BMLF1(280-288) could be cross-reactive with two influenza A virus or two other EBV epitopes. Mouse T cells specific to the vaccinia virus-encoded a11r(198-205) could be cross-reactive with three different lymphocytic choriomeningitis virus, one Pichinde virus, or one other vaccinia virus epitope. Patterns of cross-reactivity differed among individuals, reflecting the private specificities of the host's immune repertoire and divergence in the abilities of T cell populations to mediate protective immunity. Defining such cross-reactive networks between commonly encountered human pathogens may facilitate the design of vaccines.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Epstein-Barr Virus Infections/immunology , Immunity, Cellular , Vaccinia/immunology , Adolescent , Adoptive Transfer , Animals , CD8-Positive T-Lymphocytes/transplantation , CD8-Positive T-Lymphocytes/virology , Cell Line, Tumor , Cells, Cultured , Coculture Techniques , Epitopes, T-Lymphocyte/immunology , Epitopes, T-Lymphocyte/metabolism , Epstein-Barr Virus Infections/metabolism , Humans , Immunologic Memory , Influenza, Human/immunology , Lymphocyte Activation/immunology , Lymphocytic Choriomeningitis/immunology , Male , Mice , Mice, Congenic , Mice, Inbred C57BL , Vaccinia/metabolism , Young Adult
12.
Antivir Ther ; 12(3): 303-16, 2007.
Article in English | MEDLINE | ID: mdl-17591020

ABSTRACT

BACKGROUND: Strong hepatitis C virus (HCV)-specific T-cell responses are associated with spontaneous clearance of acute hepatitis C. However, recent studies described a decline in HCV-specific CD8+ T-cells during interferon treatment, suggesting that the success of acute HCV therapy might be independent of adaptive immunity. METHODS: T-cell responses of eight human leukocyte antigen (HLA)-A2-positive, acutely infected patients treated with peginterferon-alpha2b were studied by ELISPOT and proliferation assays and flow cytometry analysis using HCV-specific tetramers. RESULTS: HCV-specific T-cells predominately declined during therapy. However, diverse patterns of CD4+ and CD8+ T-cell kinetics were observed. In patients with sustained virological response chemokine receptor 3 (CXCR-3) expression of HCV-specific CD8+ T-cells was upregulated, indicating homing to the liver. Low levels of T-cells remained detectable throughout treatment and follow up. In contrast, T-cells of a relapse patient did not upregulate CXCR-3 but displayed a higher staining for annexin-V, followed by a complete loss of peripheral virus-specific CD8+ T-cells by week 12. CONCLUSIONS: Kinetics of HCV-specific T-cell responses are heterogeneous in interferon-treated patients with acute hepatitis C. The decline of T-cells might be a consequence of both apoptosis and homing. The balance between cell death and regulation of chemokine receptors might lead to different long-term outcomes.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/immunology , Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Acute Disease , Adult , Aged , Amino Acid Sequence , Annexin A5/metabolism , Binding Sites/genetics , Binding Sites/immunology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Enzyme-Linked Immunosorbent Assay , Epitopes, T-Lymphocyte/genetics , Female , Flow Cytometry , HLA-A2 Antigen/immunology , Hepacivirus/genetics , Hepatitis C/immunology , Hepatitis C/virology , Humans , Interferon alpha-2 , Lymphocyte Count , Male , Molecular Sequence Data , Polyethylene Glycols , RNA, Viral/blood , Receptors, CXCR3 , Receptors, Chemokine/metabolism , Recombinant Proteins , Species Specificity , Treatment Outcome
13.
Turk J Gastroenterol ; 16(4): 183-7, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16547844

ABSTRACT

BACKGROUND/AIMS: There are significant variations in the geographic distribution of hepatitis B virus genotypes throughout the world, and some genotypes are associated with different clinical outcomes. Eight genotypes of human hepatitis B virus (designated A-H) have been described to date. To determine the hepatitis B virus genotypes in Turkish patients with chronic liver disease and compare the results with clinical characteristics of the patients. METHODS: Fifty-four (pediatric: n=25 and adult: n=29) patients with chronic hepatitis B virus infection and with an hepatitis B virus DNA level above 5 pg/ml were entered into the trial. Restriction fragment length polymorphism method was used to determine hepatitis B virus genotype and their restriction fragment length polymorphism patterns. Hepatitis B virus DNA samples of 13 patients were sequenced automatically for further confirmation of restriction fragment length polymorphism results. RESULTS: Genotype D was the dominant genotype in all of our cases. Among six restriction fragment length polymorphism patterns of genotype D reported in the literature, three (D1, D2, D6) were present in our series and D2 was the most frequent restriction fragment length polymorphism pattern (81.5%). No significant differences were observed among different genotype D restriction fragment length polymorphism patterns with respect to patients' serum ALT, AST, and hepatitis B virus DNA titer, but D2 restriction fragment length polymorphism pattern was significantly more common in younger adults compared to D1 restriction fragment length polymorphism pattern. CONCLUSION: Genotype D with D2 restriction fragment length polymorphism pattern is the dominant hepatitis B virus genotype in all age groups in Turkey.


Subject(s)
DNA, Viral/analysis , Hepatitis B virus/genetics , Hepatitis B, Chronic/virology , Polymorphism, Restriction Fragment Length , Adolescent , Adult , Age Distribution , Aged , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Child , Child, Preschool , Female , Genome, Viral , Genotype , Hepatitis B Surface Antigens/blood , Hepatitis B Surface Antigens/immunology , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/epidemiology , Humans , Male , Middle Aged , Polymerase Chain Reaction , Prevalence , Sex Distribution , Turkey/epidemiology
14.
Turk J Gastroenterol ; 15(1): 21-6, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15264117

ABSTRACT

BACKGROUND/AIMS: A significant association between variations in amino acid sequences resides between 2209-2248 nucleotides of HCV non-structural 5A (NS5A) gene, and response to interferon treatment has been proposed. The aim of this study was to determine whether the amino acid sequence changes in ISDR could be correlated to response to alpha interferon treatment in Turkish patients infected with HCV genotypes 1b and 1a. METHODS: Thirty-nine patients with chronic C virus infection (35 and 4 patients with genotype 1b and 1a, respectively), receiving 3x3-5 MU of interferon a-2b for six months were included in the study. Following PCR amplification of the region from pre-treatment serum samples, the products were directly sequenced. The amino acid sequence of NS5A was compared with the published sequence for HCV-J (AA 2209-2248). Mutant type was defined as three or more amino acid mutations, and intermediate type as 1-3 amino acids in this region. Otherwise, they were defined as the wild type (no amino acid mutations). HCV RNA serum viremia levels were analyzed by branched DNA assay. RESULTS: Eighteen patients were responders (R; 46%), whereas 21 patients were non-responders (NR; 54%). Amino acid changes in both R and NR groups did not show significant difference. Intermediate or wild type strains were detected in both groups. CONCLUSIONS: In this study, we could not determine a significant association between number of amino acid changes in NS5A2209-2248 and response to interferon treatment. In the majority of the patients, it seems that amino acid sequences in this region are well conserved.


Subject(s)
Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Mutation , Viral Nonstructural Proteins/genetics , Adult , Base Sequence , DNA, Viral , Female , Genotype , Hepacivirus/drug effects , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/genetics , Humans , Male , Middle Aged , Molecular Sequence Data , Pharmacogenetics , Prognosis , Prospective Studies , Reverse Transcriptase Polymerase Chain Reaction/methods , Treatment Outcome , Turkey
15.
Hepatology ; 40(1): 98-107, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15239091

ABSTRACT

Early treatment of acute hepatitis C infection with interferon alfa-2b (IFN-alpha-2b) prevents chronicity in almost all patients. So far, no data are available on the long-term outcome after interferon (IFN) therapy of acute hepatitis C. The aim of this study was to assess the clinical, virological, and immunological long-term outcome of 31 successfully treated patients with acute hepatitis C infection who were followed for a median of 135 weeks (52-224 weeks) after end of therapy. None of the individuals had clinical evidence of liver disease. Alanine aminotransferase (ALT) levels were normal in all but 1 patient. Serum hepatitis C virus (HCV) RNA was negative throughout follow-up, even when investigated with the highly sensitive transcription-mediated amplification (TMA) assay (cutoff 5-10 IU/mL). In addition, no HCV RNA was detected in peripheral blood mononuclear cells (PBMC) of 15 cases tested. The patients' overall quality-of-life scores as determined by the SF-36 questionnaire did not differ from the German reference control cohort. Ex vivo interferon gamma (IFN-gamma) ELISPOT analysis detected HCV-specific CD4(+) T-helper cell reactivity in only 35% of cases, whereas HCV-specific CD8(+) T-cell responses were found in 4 of 5 HLA-A2-positive individuals. Anti-HCV antibody levels decreased significantly during and after therapy in all individuals. In conclusion, early treatment of symptomatic acute hepatitis C with IFN-alpha-2b leads to a long-term virological, biochemical, and clinical response. Waning of anti-HCV humoral immunity and presence of HCV-specific CD8(+) (but not CD4(+)) T cells highlights the complexity of T-cell and B-cell memory to HCV, which might be significantly altered by IFN treatment.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Acute Disease , Adult , Aged , Antibodies, Viral , Antibody Formation , Antibody Specificity , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Case-Control Studies , Cohort Studies , Female , Follow-Up Studies , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C/blood , Hepatitis C/immunology , Hepatitis C/virology , Histocompatibility Antigens Class II/analysis , Humans , Male , Middle Aged , RNA, Viral/blood , Treatment Outcome
16.
J Hepatol ; 37(2): 266-71, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12127433

ABSTRACT

BACKGROUND/AIMS: Interferon is the only established therapy for chronic delta hepatitis and alternative treatment options are an urgent need. Since successful treatment of a case of post-transplant delta hepatitis with the nucleoside analogue famciclovir had been reported, a pilot study was undertaken to evaluate the use of famciclovir in the treatment of chronic delta hepatitis. METHODS: A total of 15 adult patients, 13 men, two women, ages 20-52 years, with chronic delta hepatitis were treated with famciclovir, 500 mg, three times a day for 6 months and were then followed-up for 6 months posttreatment. All patients had compensated chronic liver disease, elevated liver enzymes and were hepatitis delta virus (HDV) RNA positive by polymerase chain reaction at baseline. Patients were monitored and tested for HBsAg, hepatitis B virus (HBV) DNA and HDV RNA levels. Liver biopsies were obtained before starting famciclovir and within 1 month of completion of treatment. RESULTS: HBV DNA levels decreased in nine of the 15 patients and levels rose again after treatment (P<0.05). Famciclovir had no effect on alanine aminotransferase (ALT) and HBsAg levels or on serum HDV RNA and overall, there was no improvement in liver histology. CONCLUSIONS: Treatment of chronic delta hepatitis with famciclovir has no effect on disease activity and HDV RNA levels.


Subject(s)
2-Aminopurine/analogs & derivatives , 2-Aminopurine/administration & dosage , Antiviral Agents/administration & dosage , Hepatitis D, Chronic/drug therapy , Hepatitis Delta Virus/isolation & purification , Adult , Biopsy , Famciclovir , Female , Hepatitis D, Chronic/pathology , Hepatitis Delta Virus/genetics , Humans , Liver/pathology , Liver/virology , Male , Middle Aged , Pilot Projects , RNA, Viral/analysis
17.
J Med Virol ; 66(1): 34-9, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11748656

ABSTRACT

A number of disorders for which an association with hepatitis C virus infection exist. These disorders include essential mixed cryoglobulinemia, membranoproliferative glomerulonephritis, and idiopathic pulmonary fibrosis. This study was initiated to investigate the cellular content and lymphocyte subpopulations of bronchoalveolar lavage fluid obtained from individuals with chronic hepatitis C and to compare the results to those of controls. Eighteen patients with chronic hepatitis C (male/female, 6/12) and 14 healthy volunteers (male/female, 6/8), were studied. Bronchoalveolar lavage fluid was obtained from each; and the lymphocyte subtypes and the presence of HCV-RNA in the bronchoalveolar lavage fluid were determined. All anti-HCV positive subjects were HCV-RNA positive in serum. One (5.6%) had a HCV-RNA positive bronchoalveolar lavage. The total cell and neutrophil counts of the bronchoalveolar lavage fluid were significantly greater in patients with chronic hepatitis C as compared to controls (5,799.6 +/- 957.4 x 10(3)/ml vs. 1,835.7 +/- 447.8 x 10(3)/ml, P = 0.001; 1,175.8 +/- 634.7 x 10(3)/ml vs. 53.1 +/- 28.1 x 10(3)/ml, P = 0.029). In contrast, the lymphocyte, macrophage and eosinophil counts did not differ. No difference in the percentage, median or range of individual T cell subsets or B cell numbers in the bronchoalveolar lavage fluid existed between the groups. It is concluded that hepatitis C virus infection may be associated with an occult pulmonary inflammatory reaction manifested by an increased number of polymorphonuclear neutrophils in bronchoalveolar lavage fluid. This finding may contribute to the process that leads to idiopathic pulmonary fibrosis seen in a minority of cases of chronic hepatitis C.


Subject(s)
Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Hepacivirus/immunology , Hepatitis C, Chronic/complications , Pulmonary Fibrosis/etiology , Adult , Female , Hepacivirus/isolation & purification , Hepatitis C Antibodies/blood , Hepatitis C, Chronic/immunology , Hepatitis C, Chronic/virology , Humans , Male , Middle Aged , Pulmonary Fibrosis/immunology , RNA, Viral/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...